New nasal spray could offer quick migraine relief for those on preventives

NCT ID NCT06401642

Recruiting now Symptom relief Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests zavegepant (Zavzpret), a nasal spray already approved for migraines, in 200 adults who also take CGRP-targeting preventive medications. Researchers want to see if it provides headache relief within 2 to 4 hours and improves daily function. The goal is to find a safe, effective rescue treatment for people already managing migraines with preventives.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zavegepant (Zavzpret) nasal spray
What this could lead to: If it works, this could give people on migraine preventives a fast-acting option to stop migraine attacks when they occur.
What could go wrong: This is a small, early-phase study (200 people) and results may not apply to everyone. Side effects are possible, and the drug may not work better than existing options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIGRAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MIGRAINE

Contacts and locations

Locations

Mayo Clinic in Arizona
RECRUITING

Phoenix, Arizona, 85254, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.